PTGX Q1 2023 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$36M

Net Income

-$34M

EPS (Diluted)

$-0.62

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$240M

Total Liabilities

$24M

Stockholders' Equity

$216M

Cash & Equivalents

$128M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$26M	-100.0%
Gross Profit	$0	$25M	-100.0%
Operating Income	-$36M	-$21M	-70.6%
Net Income	-$34M	-$21M	-61.1%